Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
Cardiovascular Systems (CSII) Loss Wider Than Estimates in Q1
by Zacks Equity Research
We are upbeat about the year-over-year uptick in both Coronary and peripheral device revenues within Cardiovascular Systems' (CSII) domestic market.
Accuray (ARAY) Q1 Wider Than Expected, FY20 View Retained
by Zacks Equity Research
Accuray (ARAY) reiterates revenue and adjusted EBITDA view for fiscal 2020.
Ecolab (ECL) Earnings and Revenues Miss Estimates in Q3
by Zacks Equity Research
Global Industrial unit aid Ecolab's (ECL) Q3 results; 2019 EPS view slashed.
Has Thermo Fisher Scientific (TMO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (TMO) Outperforming Other Medical Stocks This Year?
Walgreens Boots (WBA) Q4 Earnings Surpass, Margins Fall
by Zacks Equity Research
Growth within the Retail Pharmacy USA and Pharmaceutical Wholesale divisions of Walgreens Boots (WBA) is partially offset by a dull performance at Retail Pharmacy International.
Omnicell (OMCL) Beats on Q3 Earnings, Raises '19 EPS View
by Zacks Equity Research
Omnicell (OMCL) continues to see solid segmental contributions in Q3. Expansion of gross and operating margins is a positive too.
Cerner (CERN) Earnings Beat Estimates in Q3, Improve Y/Y
by Zacks Equity Research
Cerner (CERN) Q3 results benefit from higher revenues, gains in Licensed software, Technology resale, Professional and Managed services units, and international revenue growth.
NextGen (NXGN) Q2 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
NextGen (NXGN) retains its fiscal 2020 revenue and EPS guidance.
GNC Holdings (GNC) Q3 Loss Meets Estimates, Revenues Miss
by Zacks Equity Research
GNC Holdings' (GNC) third-quarter 2019 results, reflecting dismal performance across segments, disappoint investors.
TMO vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
TMO vs. EW: Which Stock Is the Better Value Option?
Illumina (ILMN) Beats Q3 Earnings Estimates, Raises View
by Zacks Equity Research
Illumina (ILMN) announces impressive Q3 results on the back of strong growth in the sequencing business.
Company News For Oct 24, 2019
by Zacks Equity Research
Companies In The News Are: ALXN,ANTM,TMO,BSX
Thermo Fisher (TMO) Beats on Q3 Earnings, Lifts Guidance
by Zacks Equity Research
We are encouraged that three out of Thermo Fisher's (TMO) four business segments have registered strong year-over-year revenue growth in Q3.
Thermo Fisher Scientific (TMO) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 2.08% and 1.33%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Earnings Roster for Oct 23: TMO, BSX & More
by Zacks Equity Research
Encouraging growth in the emerging markets despite the ongoing trade tiff is likely to contribute to revenues in the medical products space this earnings season.
What's in Store for Thermo Fisher (TMO) in Q3 Earnings?
by Zacks Equity Research
Developments in business segments are likely to have aided Thermo Fisher (TMO) in the third quarter.
Thermo Fisher Scientific (TMO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Thermo Fisher (TMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Thermo Fisher Scientific (TMO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (TMO) Outperforming Other Medical Stocks This Year?
Thermo Fisher Gets a Boost from Buyouts and Global Expansion
by Urmimala Biswas
Thermo Fisher (TMO) registers a solid international performance with strong growth in Europe and Asia-Pacific including China.
The Zacks Analyst Blog Highlights: Microsoft, Royal Dutch, IBM, Thermo Fisher and American Tower
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, Royal Dutch, IBM, Thermo Fisher and American Tower
Top Stock Reports for Microsoft, Royal Dutch Shell & IBM
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Royal Dutch Shell (RDS.A) and IBM (IBM).
Thermo Fisher Closes API Site Buyout, Fortifies Pharma Unit
by Zacks Equity Research
Following the acquisition closure of GlaxoSmithKline's plant, Thermo Fisher (TMO) will continue to manufacture APIs for the same under a multi-year supply agreement.
Here's Why You Should Add Thermo Fisher to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher's (TMO) performance.
Zacks.com featured highlights include: Booz Allen Hamilton, Thermo Fisher Scientific, Target, Microsoft and Barrel Old Country Store
by Zacks Equity Research
Zacks.com featured highlights include: Booz Allen Hamilton, Thermo Fisher Scientific, Target, Microsoft and Barrel Old Country Store
7 Dividend Growth Stocks to Buy for October
by Sweta Killa
Dividend-paying securities are a major source of consistent income for investors when returns from the equity market are at risk.